Safety profile and clinical outcomes in a phase I, placebo-controlled study of siplizumab in acute graft-versus-host disease.

scientific article published in July 2009

Safety profile and clinical outcomes in a phase I, placebo-controlled study of siplizumab in acute graft-versus-host disease. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1097/TP.0B013E3181ABFBF7
P698PubMed publication ID19623014

P2093author name stringHarry Yang
Douglas Adkins
Voravit Ratanatharathorn
Barbara White
P433issue2
P407language of work or nameEnglishQ1860
P921main subjectplaceboQ269829
P304page(s)198-202
P577publication date2009-07-01
P1433published inTransplantationQ15730500
P1476titleSafety profile and clinical outcomes in a phase I, placebo-controlled study of siplizumab in acute graft-versus-host disease.
P478volume88

Reverse relations

cites work (P2860)
Q37123276High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects.
Q37881151Moving to tolerance: clinical application of T regulatory cells
Q39948888Overcoming immunological barriers in regenerative medicine
Q40852060Preventive Anti-CD2 Treatment does not Impair Parasite Control in a Murine Toxoplasmosis Model
Q38066586Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation
Q55506612The Role of Monoclonal Antibodies in the Management of Leukemia.
Q33803804Transplantation immunology: solid organ and bone marrow
Q37600436Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases

Search more.